TY - JOUR
T1 - Use of mizoribine as a rescue drug for steroid-resistant pediatric IgA nephropathy
AU - Ikezumi, Yohei
AU - Suzuki, Toshiaki
AU - Karasawa, Tamaki
AU - Kawachi, Hiroshi
AU - Nikolic-Paterson, David J.
AU - Uchiyama, Makoto
N1 - Funding Information:
This work was supported by Grant-Aids for Scientific Research (C: No.19791633 to Y.I.) from the Ministry of Education, Culture, Sports, Science and Technology of Japan, The Mother and Child Health Foundation, and the Study Group on IgA nephropathy, as well as Grant-Aids for Promotion of Niigata University Research Projects from Niigata University.
PY - 2008/4
Y1 - 2008/4
N2 - Recent clinical trials have shown a beneficial effect of mizoribine (Miz), an immunosuppressive drug, in the treatment of new-onset pediatric IgA nephropathy (IgAN). In this study, we evaluated the efficacy of Miz treatment in three children with established steroid-resistant IgAN. The patients had IgAN featuring persistent proteinuria and diffuse mesangial proliferation and had failed to respond to 2 years of treatment with prednisolone. Based upon the second biopsy results, patients were given methylprednisolone (mPSL) pulse therapy that induced a transient reduction in proteinuria, which was reversed when the mPSL dose was tapered. Miz therapy was then instigated in place of pulse mPSL. All three patients showed a substantial reduction in proteinuria and resolution of hematuria within 5 months. A follow-up biopsy in two of the patients showed a substantial reduction in the severity of glomerular lesions and a decrease in the number of activated macrophages. In conclusion, Miz therapy was found to be a safe and effective therapy in three cases of steroid-resistant pediatric IgAN. The ability of Miz to reduce the number of activated macrophages may be an important mechanism by which this drug ameliorated renal disease in these patients.
AB - Recent clinical trials have shown a beneficial effect of mizoribine (Miz), an immunosuppressive drug, in the treatment of new-onset pediatric IgA nephropathy (IgAN). In this study, we evaluated the efficacy of Miz treatment in three children with established steroid-resistant IgAN. The patients had IgAN featuring persistent proteinuria and diffuse mesangial proliferation and had failed to respond to 2 years of treatment with prednisolone. Based upon the second biopsy results, patients were given methylprednisolone (mPSL) pulse therapy that induced a transient reduction in proteinuria, which was reversed when the mPSL dose was tapered. Miz therapy was then instigated in place of pulse mPSL. All three patients showed a substantial reduction in proteinuria and resolution of hematuria within 5 months. A follow-up biopsy in two of the patients showed a substantial reduction in the severity of glomerular lesions and a decrease in the number of activated macrophages. In conclusion, Miz therapy was found to be a safe and effective therapy in three cases of steroid-resistant pediatric IgAN. The ability of Miz to reduce the number of activated macrophages may be an important mechanism by which this drug ameliorated renal disease in these patients.
UR - http://www.scopus.com/inward/record.url?scp=40549102494&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=40549102494&partnerID=8YFLogxK
U2 - 10.1007/s00467-007-0664-2
DO - 10.1007/s00467-007-0664-2
M3 - Article
C2 - 18038158
AN - SCOPUS:40549102494
SN - 0931-041X
VL - 23
SP - 645
EP - 650
JO - Pediatric Nephrology
JF - Pediatric Nephrology
IS - 4
ER -